PMID: 19915300Nov 17, 2009Paper

Transfusion-related acute lung injury (TRALI) induced by donor-derived anti-HLA antibodies in aplastic anemia: possible priming effect of granulocyte-colony stimulating factor (G-CSF) on the recipient neutrophils

Internal Medicine
Masakatsu HishizawaTatsuharu Ohno

Abstract

Transfusion-related acute lung injury (TRALI) is currently the leading cause of transfusion-related death. A 67-year-old man with severe aplastic anemia developed TRALI, consisting of acute respiratory insufficiency with severe hypoxia and diffuse pulmonary infiltration 2 hours after the transfusion of platelet concentrates. Although he required intensive respiratory support, he promptly recovered within 4 days. The presence of anti-HLA antibody (anti-HLA B52) in the donated blood product was demonstrated, and a lymphocytotoxicity test disclosed antibody-mediated cytotoxicity against the patient's cells. Furthermore, administration of granulocyte-colony stimulating factor was suggested to predispose the patient to TRALI by priming the neutrophils.

References

Jul 11, 2000·British Journal of Haematology·A DykesA Street
Mar 26, 2004·Human Immunology·Robert A BrayHoward M Gebel
Apr 6, 2004·Developmental and Comparative Immunology·Daniel R BarredaMiodrag Belosevic
Dec 2, 2004·Blood·Christopher C SillimanLynn K Boshkov
Apr 15, 2005·Transfusion Medicine Reviews·Mindy GoldmanUNKNOWN TRALI Consensus Panel
Apr 18, 2006·Critical Care Medicine·Christopher C Silliman
May 20, 2006·The Journal of Clinical Investigation·Mark R LooneyMichael A Matthay
Mar 8, 2007·British Journal of Haematology·Jürgen Bux, Ulrich J H Sachs
Jul 27, 2007·Best Practice & Research. Clinical Anaesthesiology·Pearl Toy, Clifford Lowell

❮ Previous
Next ❯

Citations

May 29, 2014·Transfusion·Mari KonoKunihiro Funakoshi
Jun 9, 2010·Expert Review of Respiratory Medicine·Mladen Sokolovic, Stephen M Pastores
Mar 10, 2011·Current Opinion in Anaesthesiology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.